These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

440 related articles for article (PubMed ID: 37762542)

  • 41. The Potential Role of SGLT2 Inhibitors in the Treatment of Type 1 Diabetes Mellitus.
    Fattah H; Vallon V
    Drugs; 2018 May; 78(7):717-726. PubMed ID: 29663292
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Turning Foes to Friends: Knocking Down Diabetes Associated SGLT2 Transporters and Sustaining Life.
    Gupta A; Mittal S; Monika ; Dhingra R; Dhingra N
    Curr Diabetes Rev; 2020; 16(7):716-732. PubMed ID: 31951170
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The Na
    Koepsell H
    Pharmacol Ther; 2017 Feb; 170():148-165. PubMed ID: 27773781
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Focused Updates: SGLT2 Inhibitors in Patients With Heart Failure and/or Chronic Kidney Disease.
    Cheng JWM; Colucci V; Kalus JS; Spinler SA
    Ann Pharmacother; 2021 Feb; 55(2):252-260. PubMed ID: 32536199
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Renal Effects of Sodium-Glucose Co-Transporter Inhibitors.
    Thomson SC; Vallon V
    Am J Cardiol; 2019 Dec; 124 Suppl 1(Suppl 1):S28-S35. PubMed ID: 31741437
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Sodium-Glucose Cotransporter Type 2 (SGLT-2) Inhibitors and Ketogenesis: the Good and the Bad.
    Ekanayake P; Hupfeld C; Mudaliar S
    Curr Diab Rep; 2020 Nov; 20(12):74. PubMed ID: 33230620
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Therapeutic Interventions of Novel SGLT2 Inhibitors Against Metabolic Disorders: Transforming the Association into Perspectives.
    Irshad K; Akash MSH; Rehman K; Sharif H
    Endocr Metab Immune Disord Drug Targets; 2021; 21(12):2169-2180. PubMed ID: 34139987
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Sodium-glucose co-transporter-2 inhibitors: an emerging new class of oral antidiabetic drug.
    Idris I; Donnelly R
    Diabetes Obes Metab; 2009 Feb; 11(2):79-88. PubMed ID: 19125776
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Sodium-glucose co-transporter (SGLT)2 and SGLT1 renal expression in patients with type 2 diabetes.
    Solini A; Rossi C; Mazzanti CM; Proietti A; Koepsell H; Ferrannini E
    Diabetes Obes Metab; 2017 Sep; 19(9):1289-1294. PubMed ID: 28419670
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications.
    Heerspink HJ; Perkins BA; Fitchett DH; Husain M; Cherney DZ
    Circulation; 2016 Sep; 134(10):752-72. PubMed ID: 27470878
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Do sodium-glucose co-transporter-2 inhibitors prevent heart failure with a preserved ejection fraction by counterbalancing the effects of leptin? A novel hypothesis.
    Packer M
    Diabetes Obes Metab; 2018 Jun; 20(6):1361-1366. PubMed ID: 29359851
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Intrarenal Mechanisms of Sodium-Glucose Cotransporter-2 Inhibitors on Tubuloglomerular Feedback and Natriuresis.
    Koh ES; Kim GH; Chung S
    Endocrinol Metab (Seoul); 2023 Aug; 38(4):359-372. PubMed ID: 37482684
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Recent Developments in Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors as a Valuable Tool in the Treatment of Type 2 Diabetes Mellitus.
    Kumar S; Khatik GL; Mittal A
    Mini Rev Med Chem; 2020; 20(3):170-182. PubMed ID: 32134370
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A new class of drugs for heart failure: SGLT2 inhibitors reduce sympathetic overactivity.
    Sano M
    J Cardiol; 2018 May; 71(5):471-476. PubMed ID: 29415819
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The Role of the Kidney and SGLT2 Inhibitors in Type 2 Diabetes.
    Katz PM; Leiter LA
    Can J Diabetes; 2015 Dec; 39 Suppl 5():S167-75. PubMed ID: 26654860
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Ipragliflozin and other sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: preclinical and clinical data.
    Kurosaki E; Ogasawara H
    Pharmacol Ther; 2013 Jul; 139(1):51-9. PubMed ID: 23563279
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Renal physiology of glucose handling and therapeutic implications.
    Cherney DZ; Kanbay M; Lovshin JA
    Nephrol Dial Transplant; 2020 Jan; 35(Suppl 1):i3-i12. PubMed ID: 32003835
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Renal Benefits of SGLT 2 Inhibitors and GLP-1 Receptor Agonists: Evidence Supporting a Paradigm Shift in the Medical Management of Type 2 Diabetes.
    Ninčević V; Omanović Kolarić T; Roguljić H; Kizivat T; Smolić M; Bilić Ćurčić I
    Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31757028
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Impact of SGLT2 inhibitors on the kidney in people with type 2 diabetes and severely increased albuminuria.
    Shah N; Perkovic V; Kotwal S
    Expert Rev Clin Pharmacol; 2022 Jul; 15(7):827-842. PubMed ID: 35912871
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Sodium-glucose cotransporter 2 inhibition in non-diabetic kidney disease.
    Almaimani M; Sridhar VS; Cherney DZI
    Curr Opin Nephrol Hypertens; 2021 Sep; 30(5):474-481. PubMed ID: 34074889
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.